A5063194962- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- Influenza Virus Research Studies
- Leptospirosis research and findings
- Veterinary medicine and infectious diseases
- Bacterial Infections and Vaccines
- Viral Infections and Vectors
- SARS-CoV-2 detection and testing
- Animal Virus Infections Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
Erciyes University
2021-2024
The rapid spread of SARS-CoV-2 with its mutating strains has posed a global threat to safety during this COVID-19 pandemic. Thus far, there are 123 candidate vaccines in human clinical trials and more than 190 candidates preclinical development worldwide as per the WHO on 1 October 2021. various types that currently approved for emergency use include viral vectors (e.g., adenovirus, University Oxford/AstraZeneca, Gamaleya Sputnik V, Johnson & Johnson), mRNA (Moderna Pfizer-BioNTech), whole...
Development of safe and effective vaccine options is crucial to the success fight against COVID-19 pandemic. Herein, we report interim safety immunogenicity findings phase 1&2 trials ERUCoV-VAC, an inactivated whole virion SARS-CoV-2 vaccine.Double-blind, randomised, single centre, 1 2 included seronegative healthy adults aged 18-55 years (18-64 in 2). All participants, except first 4 who received ERUCoV-VAC 3 μg or 6 unblinded monitored for 7 days purposes, were assigned receive two...
CCHFV has the potential for human-to-human transmission, and there is no effective approved vaccine or treatment. Therefore, development of an against critical importance. Building on success mRNA-based vaccines during COVID-19 pandemic, this study reports a mRNA candidate expressing NP CCHFV. The in vitro transcript (IVT) was designed with pseudouridine (Ψ) nucleoside modification. As part preclinical characterization IVT candidate, biochemical immunological properties were confirmed Huh-7...
Vaccine-induced immunity wanes over time and warrants booster doses. We investigated the long-term (32 weeks) immunogenicity safety of a third, homologous, open-label dose TURKOVAC, administered 12 weeks after completion primary series in randomized, controlled, double-blind, phase 2 study. Forty-two participants included analysis were evaluated for neutralizing antibodies (NAbs) (with microneutralization (MNT50) focus reduction (FRNT50) tests), SARS-CoV-2 S1 RBD (Spike Receptor Binding...
Background: Safe and effective vaccine options is crucial to fight against COVID-19 pandemic. We report interim safety immunogenicity findings of the phase 1&2 trials ERUCoV-VAC, an inactivated whole virion SARS-CoV-2 vaccine. Methods: Double-blind, randomised, single centre, included seronegative healthy adults aged 18-55 years (18-64 in 2). Participants, were assigned receive two intramuscular doses ERUCoV-VAC 3µg or 6µg placebo 21 days apart (28 2) via computer-generated randomisation....